ABOUT Amsoki-cel (OBX-115)
An Investigational cytoTIL15™ Cell Therapy
Our lead clinical program, amsoki-cel, is an investigational TIL cell therapy engineered to express membrane-bound IL15 (mbIL15), which is designed to support TIL activity with the goal of improving depth and durability of response. By expressing mbIL15 directly on engineered TIL, amsoki-cel eliminates the need for administration of IL2, a standard component of conventional non-engineered TIL cell therapy that can be associated with substantial side effects.
Benefits of engineered TIL expressing mbIL15 vs. administration of systemic IL2
Amoski-cel (OBX-115) is manufactured without using IL2 in the rapid expansion protocol (REP) phase and is designed to be used without IL2 administration in the treatment regimen.
Elimination of IL2 from the TIL treatment regimen is a meaningful advantage. Systemic IL2 therapy is associated with substantial side effects and is expensive and complicated to administer. Eliminating IL2 is projected to expand patient eligibility by enabling treatment of patients who cannot tolerate or access IL2.
Our proprietary, differentiated manufacturing process drives a desirable TIL phenotype (CD8+ T cells, memory T cells) and generates less-exhausted cells, which is anticipated to improve clinical outcomes in patients.
Our Clinical Trial
Agni-01 Multicenter Trial in Advanced Solid Tumors: NCT06060613
We are investigating amsoki-cel (OBX-115) and enrolling patients in the ongoing Agni-01 Phase 1/2 multicenter clinical trial in advanced solid tumors, including unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC), with study sites across the US and Australia.
The primary objectives of the Agni-01 trial are to assess the safety, tolerability, and preliminary efficacy of the amsoki-cel regimen in adult patients with advanced or metastatic melanoma resistant to immune checkpoint inhibitors. The safety, tolerability, and preliminary efficacy of the amsoki-cel regimen is also being investigated in patients with relapsed or refractory metastatic NSCLC.
Patients who choose to enroll in our clinical trials are contributing to our understanding of the safety and efficacy of our investigational product candidate(s). We are grateful for the patients and families who help us advance our mission to deliver transformative outcomes for patients.
Please contact OBX115-2301TRIAL@obsidiantx.com for more information.
